UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 260,194 Shares of Twist Bioscience Corporation $TWST

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 31.6% in the 2nd quarter, Holdings Channel reports. The firm owned 563,782 shares of the company’s stock after selling 260,194 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Twist Bioscience were worth $58,002,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of TWST. Royal Bank of Canada raised its position in Twist Bioscience by 11.8% during the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after purchasing an additional 4,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Twist Bioscience by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock valued at $2,765,000 after buying an additional 3,181 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Twist Bioscience by 4.2% during the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock valued at $36,629,000 after acquiring an additional 37,577 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of Twist Bioscience by 18.9% during the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock valued at $1,135,000 after purchasing an additional 4,591 shares during the last quarter. Finally, Norges Bank purchased a new stake in Twist Bioscience in the second quarter valued at about $737,000.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TWST. Barclays boosted their price objective on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Canaccord Genuity Group boosted their price target on Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Guggenheim reiterated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 24th. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Finally, Leerink Partners set a $110.00 price target on shares of Twist Bioscience in a research note on Thursday, July 16th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and an average target price of $98.30.

Insider Activity at Twist Bioscience

In other news, CFO Adam Laponis sold 2,399 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the transaction, the chief financial officer directly owned 110,276 shares in the company, valued at $10,402,335.08. This trade represents a 2.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 291 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $87.32, for a total value of $25,410.12. Following the transaction, the senior vice president owned 120,414 shares of the company’s stock, valued at $10,514,550.48. This trade represents a 0.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 193,099 shares of company stock worth $24,026,581. 3.08% of the stock is owned by corporate insiders.

Twist Bioscience Stock Down 0.8%

NASDAQ TWST opened at $131.00 on Thursday. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The firm has a market cap of $8.22 billion, a PE ratio of -59.01 and a beta of 2.22. The business’s fifty day simple moving average is $109.76 and its 200-day simple moving average is $75.81. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $155.44.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. During the same period last year, the company earned $0.33 EPS. The business’s quarterly revenue was up 23.2% on a year-over-year basis. As a group, equities analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.